To view this email as a web page, click here.
January 9, 2019
 
Clinical studies in melanoma
 
Incognito may be the way to go in melanoma fight
Combining antibody IgG2a with a TNF protein shows promise against melanoma in mouse studies.
 
Skin rash post target therapy may be a “cytokine storm”
Doctors suggest that cytokine antagonists may lessen the severity of the rash.
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.